Neurotrophic factors

Sep 20, 2019

ZRT Laboratory Launches Serum Test for Brain-Derived Neurotrophic Factor (BDNF)

Jun 25, 2019

Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease

Mar 25, 2019

AlzeCure to Present at International Scientific Conference

Jan 16, 2019

Neurotech Pharmaceuticals, Inc. and Lowy Medical Research Institute Announce Publication of NT-501 Phase 2 Results

Jan 03, 2019

Dompé announces first treatment with Oxervate(TM) eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)

Oct 23, 2018

CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders

Aug 22, 2018

Dompé receives FDA approval of Oxervate(TM) eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

May 18, 2018

Growth Factors (Blood and Tissue) - 2018 Global Strategic Business Report Analysis & Forecasts (2016-2024) - Burgeoning Global Population Offers Significant Growth Opportunities

Jul 20, 2017

Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompé Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy

Jun 20, 2017

Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia